Financial Data and Key Metrics Changes - The company achieved a revenue of approximately RMB 22.7 billion in 2022, representing a growth of 12.2% compared to 2021 [2][3][8] - The gross profit for the group in 2022 was RMB 3.06 billion, with a significant contribution from the sales of human albumin injection, which increased by approximately RMB 2.84 billion due to stable supply and a mature sales network [2][3][8] - The total assets of the company increased from RMB 12.52 billion in 2020 to RMB 14.24 billion in 2022 [8] Business Line Data and Key Metrics Changes - The main product, human albumin injection, generated revenue of RMB 22.57 billion in 2022, accounting for 99.4% of total revenue, with a year-on-year growth of 14.4% [8][11] - The company also reported an increase in revenue from the medical aesthetics segment, which rose by RMB 0.12 billion following the acquisition of De Mei Medical Beauty Hospital [3][4] Market Data and Key Metrics Changes - The company has established a marketing network covering major cities and terminal hospitals across China, with import operations at key ports including Beijing, Shanghai, Guangzhou, and Chengdu [2][3] - The company is positioned as a leading player in the blood products market, with a significant share in the southwest region of China [3][4] Company Strategy and Development Direction - The company is focusing on three main development tracks: traditional biological products, the new medical aesthetics industry chain, and the establishment of a supply chain service center [8][11] - The strategy includes investment and acquisition to introduce new products and expand existing markets, aiming to transform into a large-scale professional biopharmaceutical enterprise [8][11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of exchange rate fluctuations on procurement costs, particularly due to the depreciation of the RMB against the USD [3][16] - The company remains optimistic about future profitability, expecting to recover and grow as new products in the medical aesthetics segment are launched [17][18] Other Important Information - The company has established a research and development center for medical aesthetics in Chengdu, focusing on biodegradable materials and cosmetic products [5][6] - The company has received exclusive authorization for human albumin from various international manufacturers, enhancing its market position [2][3] Q&A Session Summary Question: What is the impact of the acquisition of De Mei Medical Beauty Hospital on the company's industry chain in the medical aesthetics sector? - The acquisition is expected to enhance the company's capabilities in the medical aesthetics sector, providing a platform for product testing and clinical trials [13][14] Question: Will the company maintain its dividend policy in the future? - The management indicated that the company plans to continue its dividend policy based on investment and profit conditions [11][12] Question: How does the company plan to balance its focus between blood products and medical aesthetics? - The company aims to develop both sectors simultaneously, leveraging its stable cash flow from blood products to support investments in medical aesthetics [11][12] Question: What are the expected tax benefits for the company in the medical aesthetics sector? - The company is exploring tax incentives related to high-tech enterprises, which could provide a 15% income tax reduction upon qualification [16]
兴科蓉医药(06833) - 2022 Q4 - 业绩电话会